natgillin/translations-raw huggingface dataset:
Premedication in cats before induction and maintenance of general anaesthesia with ketamine.
Priprava na operacije pri mačkah pred uvajanjem in vzdrževanjem splošne anestezije s ketaminom.
Premedication in dogs before induction and maintenance of general anaesthesia.
Priprava na operacije pri psih pred uvajanjem in vzdrževanjem splošne anestezije.
Do not use in puppies below 6 months of age or in kittens below 5 months of age.
Ne uporabite pri kužkih, mlajših od 6 mesecev, ali mačkah, mlajših od 5 mesecev.
In case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician but DO NOT DRIVE as sedation and changes in blood pressure may occur.
V primeru oralnega zaužitja ali samoinjiciranja nemudoma poiščite zdravniško pomoč in zdravniku pokažite nalepko na embalaži, vendar NE VOZITE, saj lahko pride do sedacije in sprememb v krvnem pritisku.
Avoid skin, eye or mucosal contact; the use of impermeable gloves is advisable.
Priporočljiva je uporaba nepropustnih rokavic.
If pregnant women handle the product, special caution should be observed not to self-inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.
Če izdelek uporabljajo noseče ženske, je potrebno posebno paziti, da ne pride do samoinjiciranja, saj lahko po naključnem sistemskem izpostavljanju pride do materničnih popadkov in zmanjšanja krvnega pritiska ploda.
Advice to doctors:
Nasvet zdravnikom:
Dexdomitor is an α 2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia.
Dexdomitor je agonist α2- adrenoreceptor, simptomi po vpitju lahko vključujejo klinične učinke, vključno s sedacijo (odvisno od odmerka), dihalnim zastojem, bradikardijo, hipotenzijo, suha usta in hiperglikemijo.
The specific α 2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifičen antagonist α2 adrenoceptorja, odobren za uporabo pri malih živalih, je bil pri človeku uporabljen kot antagonist učinkov deksmedetomidina samo poskusno.
Persons with known hypersensitivity to the active substance or any of the excipients should administer the product with caution.
Osebe z znano preobčutljivostjo na aktivno učinkovino ali katerokoli pomožno snov morajo previdno uporabljati zdravilo.
3 4.6 Adverse reactions (frequency and seriousness)
Neželeni učinki (pogostost in resnost)
By virtue of its α 2-adrenergic activity, dexmedetomidine causes a decrease in heart rate and body temperature.
Deksmedetomidin zaradi α2- adrenergičnega delovanja povzroča zmanjšanje srčnega utripa in telesne temperature.
Due to peripheral vasoconstriction and venous desaturation in the presence of normal arterial oxygenation, the mucous membranes may appear pale and/ or with a blue tinge.
Zaradi periferne vazokonstrikcije in venske desaturacije ob normalni arterijski oksigenaciji so lahko sluznice videti blede in/ ali modrikaste.
Vomiting may occur 5-10 minutes after injection.
5– 10 minut po injiciranju lahko pride do bruhanja.
Corneal opacities may occur during sedation (see also section 4.5).
Med sedacijo lahko roženica postane motna (gl. tudi točko 4. 5).
When dexmedetomidine and ketamine are used sequentially, with a 10 minute interval, cats may occasionally experience AV-block or extrasystole.
Pri zaporedni uporabi deksmedetomidina in ketamina z 10- minutnim presledkom lahko pri mačkah pride do občasnih AV- blokov ali ekstrasistol.
In clinical trials the incidence of hypoxaemia was common, especially within the 15 first minutes into dexmedetomidine-ketamine anaesthesia.
Pri kliničnih raziskavah je bila hipoksemija pogosta, zlasti v prvih 15 minutah deksmedetomidino- ketaminske anestezije.
When dexmedetomidine and butorphanol are used concomitantly in dogs, bradypnoea, tachypnoea, an irregular respiratory pattern (20-30 sec apnoea followed by several rapid breaths), hypoxaemia, muscle twitch or tremor or paddling, excitation, hypersalivation, retching, vomiting, urination, skin erythema, a sudden arousal, or prolonged sedation may occur.
Pri sočasni uporabi deksmedetomidina in butorfanola se pri psih lahko pojavijo upočasnjeno ali pospešeno dihanje, nepravilni dihalni vzorci (20– 30 sekund apneje, ki jim sledi nekaj hitrih vdihov), hipoksemija, trzanje mišic ali drhtenje ali brcanje, razdraženje, povečano izločanje sline, bljuvanje, bruhanje, uriniranje, kožni eritem, nenadno prebujanje ali dolgotrajna sedacija.
These may include profound sinus bradycardia, 1st and 2nd degree AV block, sinus arrest or pause, as well as atrial, supraventricular and ventricular premature complexes.
Mednje lahko sodijo globoka sinusna bradikardija, AV - blok prve in druge stopnje, sinusni zastoj ali prekinitev, prav tako prezgodnji preddvorni, nadprekatni in prekatni kompleksi.
Brady- and tachyarrhythmias have been reported and include profound sinus bradycardia, 1st and 2nd degree AV block and sinus arrest.
Poročali so o bradi - in tahiaritmijah, med katere spadajo izrazita sinusna bradikardija, AV- blok prve in druge stopnje ter sinusni zastoj.
Supraventricular and ventricular premature complexes, sinus pause and 3rd degree AV block may be observed in rare cases.
V redkih primerih lahko opazimo prezgodnje supraventrikularne in ventrikularne komplekse, sinusno prekinitev in AV- blok tretje stopnje.
Within 15 minutes dogs are normally awake and standing.
Psi so ponavadi budni in stojijo po 15 minutah.
After administration of 40 micrograms dexmedetomidine/ kg bw intramuscularly concurrently with 5 mg ketamine/ kg bw to cats, the maximum concentration of dexmedetomidine increased twofold but there was no effect on T max.
Po intramuskularni uporabi 40 mikrogramov deksmedetomidina/ kg telesne teže skupaj s 5 mg ketamina/ kg telesne teže se je najvišja koncentracija povečala dvakrat, vendar ni bilo učinka na Tmax.
The mean half-life of elimination of dexmedetomidine increased to 1.6 h and the total exposure (AUC) increased by 50%.
Srednja vrednost razpolovnega časa izločanja deksmedetomidina se je povečala na 1, 6 h, skupna izpostavljenost (AUC) pa za 50%.
4 A dose of 10 mg ketamine/ kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
4 Uporaba odmerka 10 mg ketamina/ kg skupaj s 40 mikrogrami deksmedetomidina/ kg lahko povzroči tahihardijo.
For information on adverse reactions, see section 4.6. Adverse reactions.
Za dodatne informacije o neželenih učinkih glejte 4. 6, Stranski učinki.
For information on target animal safety in cases of overdosing, see section 4.10. Overdose
Za informacije o varnosti v primeru prevelikega odmerjanja pri ciljnih živalih glejte 4. 10, Preveliko odmerjanje.
The product is intended for:
To zdravilo je namenjeno uporabi pri:
- Dogs: intravenous or intramuscular use
- Psi: intravenska in intramuskularna uporaba
- Cats: intramuscular use
- Mačke: intramuskularna uporaba
Dexdomitor, butorphanol and/ or ketamine can be mixed in the same syringe as they have been shown to be pharmaceutically compatible.
Dexdomitor, butorfanol in/ ali ketamin lahko zmešate v isti brizgi, saj so dokazano farmacevtsko združljivi.
The doses for dogs are based on body surface area.
Odmerki pri psih temeljijo na telesni površini.
The intravenous dose is 375 micrograms/ square metre body surface area and the intramuscular dose is 500 micrograms/ square metre body surface area when dexmedetomidine is used as the only agent for sedation and analgesia.
Intravenski odmerek je 375 mikrogramov/ kvadratni meter telesne površine, intramuskularni odmerek pa je 500 mikrogramov/ kvadratni meter telesne površine, kadar je deksmedetomidin uporabljen kot edina učinkovina za sedacijo in analgezijo.
When administering in conjunction with butorphanol (0.1 mg/ kg) for deep sedation and analgesia, the intramuscular dose is 300 micrograms/ square metre body surface area The premedication dose of dexmedetomidine is 125 – 375 micrograms/ square metre body surface area, administered 20 minutes prior to induction for procedures requiring anaesthesia.
Odmerek deksmedetomidina za pripravo na kirurški poseg je 125– 375 mikrogramov/ kvadratni meter telesne površine, dati pa ga je treba 20 minut pred začetkom postopka, za katerega je anestezija potrebna.
In a clinical study, the requirement for propofol and thiopental was reduced by 30% and 60% respectively.
V klinični študiji je bila potreba po propofolu zmanjšana za 30%, po tiopentalu pa za 60%.
In a clinical study, dexmedetomidine contributed to postoperative analgesia for 0.5 – 4 hours.
V klinični študiji je deksmedetomidin prispeval k pooperativni analgeziji, ki je trajala 0, 5– 4 ure.
5 Dogs Single-use sedation and analgesia
5 Psi Sedacija in analgezija za enkratno uporabo
375 mcg/ m2 intravenously
375 mikrogramov/ m2 intravensko
500 mcg/ m2 intramuscularly
500 mikrogramov/ m2 intramsukularno
(mcg/ kg) 28.1 25 23 19.6 16.8 15.7 14.6 13.4 12.6 12 11.6 11 10.5 10.1 9.8 9.5 9.3 9 8.7
(mikrogramov/ kg) 28, 1 25 23 19, 6 16, 8 15, 7 14, 6 13, 4 12, 6 12 11, 6 11 10, 5 10, 1 9, 8 9, 5 9, 3 9 8, 7
(ml) (mcg/ kg) 0.12 40 0.17 35 0.2 30 0.29 25 0.38 23 0.44 21 0.51 20 0.6 18 0.69 17 0.75 16 0.81 15 0.9 14.5 0.99 14 1.06 13.5 1.13 13 1.19 12.8 1.26 12.5 1.35 12.3 1.42 12
(ml) (mikrogramov/ kg) 0, 12 40 0, 17 35 0, 2 30 0, 29 25 0, 38 23 0, 44 21 0, 51 20 0, 6 18 0, 69 17 0, 75 16 0, 81 15 0, 9 14, 5 0, 99 14 1, 06 13, 5 1, 13 13 1, 19 12, 8 1, 26 12, 5 1, 35 12, 3 1, 42 12
For deep sedation and
Za globoko sedacijo in
For premedication prior to general anaesthesia
Za pripravo na splošno anestezijo
analgesia with butorphanol
analgezijo z butorfanolom
Dexmedetomidine Dexmedetomidine
Deksmedetomidin Deksmedetomidin
300 mcg/ m2 125 mcg/ m2 intramuscularly intramuscularly
125 mikrogramov/ m2
375 mcg/ m2 intramuscularly
375 mikrogramov/ m2
(kg) 2-3 3-4 4-5 5-10 10-13 13-15 15-20 20-25 25-30 30-33 33-37 37-45 45-50 50-55 55-60 60-65 65-70 70-80 > 80
2– 3 3– 4 4– 5 5– 10 10– 13 13– 15 15– 20 20– 25 25– 30 30– 33 33– 37 37– 45 45– 50 50– 55 55– 60 60– 65 65– 70 70– 80 > 80
(mcg/ kg) 24 23 22.2 16.7 13 12.5 11.4 11.1 10 9.5 9.3 8.5 8.4 8.1 7.8 7.6 7.4 7.3 7
24 23 22, 2 16, 7 13 12, 5 11, 4 11, 1 10 9, 5 9, 3 8, 5 8, 4 8, 1 7, 8 7, 6 7, 4 7, 3 7
(ml) (mcg/ kg) 0.12 9.4 0.16 8.3 0.2 7.7 0.25 6.5 0.3 5.6 0.35 5.2 0.4 4.9 0.5 4.5 0.55 4.2 0.6 4 0.65 3.9 0.7 3.7 0.8 3.5 0.85 3.4 0.9 3.3 0.95 3.2 1 3.1 1.1 3 1.2 2.9
0, 12 9, 4 0, 16 8, 3 0, 2 7, 7 0, 25 6, 5 0, 3 5, 6 0, 35 5, 2 0, 4 4, 9 0, 5 4, 5 0, 55 4, 2 0, 6 4 0, 65 3, 9 0, 7 3, 7 0, 8 3, 5 0, 85 3, 4 0, 9 3, 3 0, 95 3, 2 1 3, 1 1, 1 3 1, 2 2, 9
(ml) (mcg/ kg) 0.04 28.1 0.05 25 0.07 23 0.1 19.6 0.13 16.8 0.15 15.7 0.17 14.6 0.2 13.4 0.23 12.6 0.25 12 0.27 11.6 0.3 11 0.33 10.5 0.35 10.1 0.38 9.8 0.4 9.5 0.42 9.3 0.45 9 0.47 8.7
0, 04 28, 1 0, 05 25 0, 07 23 0, 1 19, 6 0, 13 16, 8 0, 15 15, 7 0, 17 14, 6 0, 2 13, 4 0, 23 12, 6 0, 25 12 0, 27 11, 6 0, 3 11 0, 33 10, 5 0, 35 10, 1 0, 38 9, 8 0, 4 9, 5 0, 42 9, 3 0, 45 9 0, 47 8, 7
(ml) 0.12 0.15 0.2 0.29 0.38 0.44 0.51 0.6 0.69 0.75 0.81 0.9 0.99 1.06 1.13 1.19 1.26 1.35 1.42
0, 12 0, 15 0, 2 0, 29 0, 38 0, 44 0, 51 0, 6 0, 69 0, 75 0, 81 0, 9 0, 99 1, 06 1, 13 1, 19 1, 26 1, 35 1, 42
6 CATS:
6 MAČKE:
The dosage for cats is 40 micrograms dexmedetomidine hydrochloride/ kg bw equal to a dose volume 0.08 ml Dexdomitor/ kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Odmerek za mačke je 40 mikrogramov deksmedetomidinklorida/ kg telesne teže, kar ustreza prostorninskemu odmerku 0, 08 ml Dexdomitorja/ kg telesne teže pri uporabi za neinvazivne, blago do zmerno boleče postopke in preglede mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
Anaesthesia can be induced 10 minutes after premedication by intramuscular administration of a target dose of 5 mg ketamine/ kg bw.
10 minut po pripravi na operacijo lahko začnete anestezijo z intramuskularnim odmerkom 5 mg ketamina/ kg telesne teže.
Cats For single-use sedation and analgesia or for premedication
Sedacija in analgezija za enkratno uporabo ali pripravo na kirurški poseg
Dexmedetomidine 40 mcg/ kg intramuscularly
Teža Deksmedetomidin 40 mikrogramov/ kg intramuskularno (kg) 2– 3 3– 4 4– 6 6– 7 7– 8 8– 10
(mcg/ kg) 40 40 40 40 40 40
(mikrogramov/ kg) 40 40 40 40 40 40
The expected sedative and analgesic effects are reached within 15 minutes after administration and are maintained up to 60 minutes after administration.
Učinki trajajo do 60 minut po uporabi.
Water may be given ad libitum.
Vodo lahko pijejo ad libitum.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
4. 10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi)
In cases of overdosage, or if the effects of dexmedetomidine become potentially life- threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, uporabite odmerek atipamezola, 10- krat večji od prvotnega odmerka deksmedetomidina (v mikrogramih/ kg telesne teže ali mikrogramih/ kvadratni meter telesne površine).
The dose volume of atipamezole at the concentration of 5 mg/ ml equals the dose volume of Dexdomitor that was given to the dog, regardless of route of administration of Dexdomitor.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ ml ustreza volumnu odmerka Dexdomitorja, ki je bil dan psu, ne glede na način uporabe Dexdomitorja.
In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose:
V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, uporabite atipamezol v obliki intramuskularne injekcije v naslednjem odmerku:
5 times the initial dose dexmedetomidine in micrograms/ kg bw.
5- kratni prvotni odmerek deksmedetomidina v mikrogramih/ kg telesne teže.
After concurrent exposure to a triple (3X) overdose of dexmedetomidine and 15 mg ketamine/ kg, atipamezole can be administered at the recommended dose level for reversal of effects induced by dexmedetomidine.
Po zaporedni izpostavitvi trojnemu (3- kratnemu) odmerku deksmedetomidina in 15 mg ketamina/ kg lahko za preobrat učinkov deksmedetomidina uporabite atipamezol v priporočenem odmerku.
Pharmacotherapeutic group: psycholeptic, ATCvet code:
Farmakoterapevtska skupina: psiholeptik, oznaka ATCvet:
7 5.1 Pharmacodynamic properties
7 5. 1 Farmakodinamične lastnosti
Dexdomitor contains dexmedetomidine as the active substance, which produces sedation and analgesia in dogs and cats.
Dexdomitor kot aktivno snov vsebuje deksmedetomidin, ki pri psih in mačkah deluje kot sedativ in analgetik.
Dexmedetomidine is a potent and selective α 2-adrenoceptor agonist that inhibits the release of noradrenaline from noradrenergic neurons.
Deksmedetomidin je močan in selektiven agonist α2- adrenoceptorja, ki zavira sproščanje noradrenalina iz noradrenergičnih nevronov.
Reduced heart rate and temporary AV-block can be seen after administration of dexmedetomidine.
Po uporabi deksmedetomidina lahko opazimo upočasnjeno delovanje srca in začasni AV- blok.
Dexmedetomidine also induces a number of other α 2-adrenoceptor mediated effects, which include piloerection, depression of motor and secretory functions of the gastrointestinal tract, diuresis and hyperglycaemia.
Mednje sodijo piloerekcija, upadanje motoričnih in sekretornih funkcij prebavil, diureza in hiperglikemija.
Dexmedetomidine is also rapidly distributed in the body and penetrates the blood-brain barrier readily.
Deksmedetomidin se tudi hitro razširi po telesu in zlahka preide skozi možgansko zaporo.
In the circulation, dexmedetomidine is largely bound to plasma proteins (> 90%).
Deksmedetomidin se v krvi večinoma veže na plazemske beljakovine (> 90%).
After an intramuscular dose of 50 micrograms/ kg a maximum concentration in plasma of about 12 ng/ ml is reached after 0.6 hours.
Po intramuskularnem odmerku v višini 50 mikrogramov/ kg je najvišja koncentracija v plazmi, približno 12 ng/ ml, dosežena po 0, 6 ure.
The bioavailability of dexmedetomidine is 60% and the apparent volume of distribution (Vd) is 0.9 l/ kg.
Biološka razpoložljivost deksmedetomidina je 60- odstotna in navidezni volumen porazdelitve (Vd) je 0, 9 l/ kg.
The elimination half-life (t½) is 40-50 minutes.
Razpolovni čas izločanja (t½) je 40– 50 minut.
Major biotransformations in the dog include hydroxylation, glucuronic acid conjugation and N-methylation in the liver.
Med večje biološke transformacije pri psih sodijo hidroksilacija, konjugacija glukuronske kisline in N - metilacija v jetrih.
The maximum plasma concentration is reached about 0.24 h after intramuscular administration.
Najvišja koncentracija v plazmi je dosežena približno 0, 24 ure po intramuskularni uporabi.
After a 40 micrograms/ kg bw intramuscular dose the Cmax is 17 ng/ ml.
Po odmerku 40 mikrogramov/ kg telesne teže je najvišja koncentracija (Cmax) 17 ng/ ml.
The apparent volume of distribution (Vd) is 2.2 l/ kg and the elimination half-life (t½) is one hour.
Navidezni volumen porazdelitve (Vd) je 2, 2 l/ kg, razpolovni čas izločanja (t½) pa ena ura.
Methyl parahydroxybenzoate (E 218) Propyl parahydroxybenzoate (E 216)
Metilparahidroksibenzoat (E 218) Propilparahidroksibenzoat (E 216)
Dexdomitor is compatible with butorphanol and ketamine in the same syringe at least for two hours.
Dexdomitor je združljiv z butorfanolom in ketaminom v isti brizgi najmanj dve uri
8 6.3 Shelf life
8 6. 3 Rok uporabnosti
After withdrawal of the first dose, the product may be stored for 28 days at 25ºC.
Po uporabi prvega odmerka izdelek lahko hranite 28 dni pri 25°C.
Do not freeze.
Ne sme zmrzniti.
Cardboard box with 1 glass (Type I) vial of 10ml with a chlorobutyl or bromobutyl rubber stopper and aluminium cap.
Kartonska škatla z eno 10- mililitrsko stekleno vialo (vrste I) z gumijastim zamaškom iz klorobutilne ali bromobutilne gume in aluminijasto zaporko.
Orion Corporation Orionintie 1 FIN-02200 Espoo Finland
Orion Corporation Orionintie 1 FIN- 02200 Espoo Finska
13 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
13 PODATKI NA ZUNANJI OVOJNINI
One ml contains 0.5 mg dexmedetomidine hydrochloride equivalent to 0.42 mg dexmedetomidine
1 ml vsebuje 0, 5 mg deksmedetomidinklorida, ki ustreza 0, 42 mg deksmedetomidina
Dogs: intravenous or intramuscular use Cats: intramuscular use Read the package leaflet before use.
Psi: intravenska in intramuskularna uporaba Mačke: intramuskularna uporaba Pred uporabo preberite navodilo za uporabo.
EXP: month/ year Shelf life after first opening:
EXP: mesec/ leto Rok trajanja po prvem odpiranju:
28 days at 25°C.
28 dni pri 25°C.
For animal treatment only – to be supplied only on veterinary prescription.
Samo za živali - oskrba le na podlagi veterinarskega recepta.
15 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS/ MULTI PACKAGE
15 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH / VEČ- PAKETNI
VIAL/ MULTI PACKAGE
VIALA / VEČ- PAKETNI
0.5 mg/ ml Dexmedetomidine hydrochloride
0, 5 mg/ ml deksmedetomidinklorida
EXP: month/ year
EXP: mesec/ leto
Orion Corporation Orionintie 1 FIN-02200 Espoo Finland
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA SPROSTITEV SERIJ V EGP, ČE STA RAZLIČNA
Active substance:
Aktivna učinkovina:
One ml contains 0.5 mg dexmedetomidine hydrochloride equivalent to 0.42 mg dexmedetomidine.
1 ml vsebuje 0, 5 mg deksmedetomidinklorida, ki ustreza 0, 42 mg deksmedetomidina
Methyl parahydroxybenzoate (E 218) 1.6 mg/ ml Propyl parahydroxybenzoate (E 216) 0.2 mg/ ml
Metilparahidroksibenzoat (E 218) 1, 6 mg/ ml Propilparahidroksibenzoat (E 216) 0, 2 mg/ ml
By virtue of its α 2-adrenergic activity, dexmedetomidine causes decreases in heart rate and body temperature.
Deksmedetomidin zaradi α2- adrenergičnega delovanja povzroča znižanje srčnega utripa in telesne temperature.
Blood pressure will increase initially and then return to normal or below normal.
Krvni pritisk se najprej poviša in se nato se vrne na normalno raven ali pod njo.
18 In some dogs and cats a decrease in respiratory rate may occur.
Pri nekaterih psih in mačkah se lahko zmanjša hitrost dihanja.
Pulmonary oedema may be observed in rare cases.
V redkih primerih so poročali o pljučnem edemu.
Vomiting may occur 5-10 minutes after injection.
18 5– 10 minut po injiciranju lahko pride do bruhanja.
When dexmedetomidine and butorphanol are used concomitantly in dogs bradypnoea, tachypnoea, an irregular respiratory pattern (20-30 sec apnoea followed by several rapid breaths), hypoxaemia, muscle twitch or tremor or paddling, excitation, hypersalivation, retching, vomiting, urination, skin erythema, a sudden arousal, or prolonged sedation may occur.
Pri sočasni uporabi deksmedetomidina in butorfanola se lahko pri psih pojavijo upočasnjeno ali pospešeno dihanje, nepravilni dihalni vzorci (20– 30 sekund apneje, ki jim sledi nekaj hitrih vdihov), hipoksemija, trzanje mišic ali drhtenje ali brcanje, razdraženje, povečano izločanje sline, bljuvanje, bruhanje, uriniranje, kožni eritem, nenadno prebujanje ali dolgotrajna sedacija.
Dexdomitor, butorphanol and/ or ketamine can be mixed in the same syringe as they have been shown to be pharmacologically compatible.
Dexdomitor, butorfanol in/ ali ketamin lahko zmešate v isti brizgi, saj so dokazano farmacevtsko združljivi.
19 DOGS:
PSI:
The intravenous dose is 375 micrograms/ square metre body surface area and the intramuscular dose is 500 micrograms/ square metre body surface area when dexmedetomidine is used as the only agent for sedation and analgesia.
Intravenski odmerek je 375 mikrogramov/ kvadratni meter telesne površine, intramuskularni odmerek pa 500 mikrogramov/ kvadratni meter telesne površine, kadar je deksmedetomidin uporabljen kot edina učinkovina za sedacijo in analgezijo.
When administering in conjunction with butorphanol (0.1 mg/ kg) for deep sedation and analgesia, the intramuscular dose is 300 micrograms/ square metre body surface area.
Pri skupni uporabi z butorfanolom (0, 1 mg/ kg) za globoko sedacijo in analgezijo je intramuskularni odmerek 300 mikrogramov/ kvadratni meter telesne površine.
The premedication dose of dexmedetomidine is 125 – 375 micrograms/ square metre body surface area, administered 20 minutes prior to induction for procedures requiring anaesthesia.
Odmerek deksmedetomidina za pripravo na kirurški poseg je 125– 375 mikrogramov/ kvadratni meter telesne površine, dati pa ga je treba 20
The dose should be adjusted to the type of surgery, length of procedure and patient temperament.
19 minut pred začetkom postopka, za katerega je anestezija potrebna.
Dogs Single-use sedation and analgesia
Psi Sedacija in analgezija za enkratno uporabo
20 Dogs
20 Psi
Weight
300 mikrogramov/ m2
(mcg/ kg) 24 23 22.2 16.7 13 12.5 11.4 11.1 10 9.5 9.3 8.5 8.4 8.1 7.8 7.6 7.4 7.3 7
(mikrogramov/ kg) 24 23 22, 2 16, 7 13 12, 5 11, 4 11, 1 10 9, 5 9, 3 8, 5 8, 4 8, 1 7, 8 7, 6 7, 4 7, 3 7
(ml) (mcg/ kg) 0.12 9.4 0.16 8.3 0.2 7.7 0.25 6.5 0.3 5.6 0.35 5.2 0.4 4.9 0.5 4.5 0.55 4.2 0.6 4 0.65 3.9 0.7 3.7 0.8 3.5 0.85 3.4 0.9 3.3 0.95 3.2 1 3.1 1.1 3 1.2 2.9
(ml) (mikrogramov/ kg) 0, 12 9, 4 0, 16 8, 3 0, 2 7, 7 0, 25 6, 5 0, 3 5, 6 0, 35 5, 2 0, 4 4, 9 0, 5 4, 5 0, 55 4, 2 0, 6 4 0, 65 3, 9 0, 7 3, 7 0, 8 3, 5 0, 85 3, 4 0, 9 3, 3 0, 95 3, 2 1 3, 1 1, 1 3 1, 2 2, 9
(ml) (mcg/ kg) 0.04 28.1 0.05 25 0.07 23 0.1 19.6 0.13 16.8 0.15 15.7 0.17 14.6 0.2 13.4 0.23 12.6 0.25 12 0.27 11.6 0.3 11 0.33 10.5 0.35 10.1 0.38 9.8 0.4 9.5 0.42 9.3 0.45 9 0.47 8.7
(ml) (mikrogramov/ kg) 0, 04 28, 1 0, 05 25 0, 07 23 0, 1 19, 6 0, 13 16, 8 0, 15 15, 7 0, 17 14, 6 0, 2 13, 4 0, 23 12, 6 0, 25 12 0, 27 11, 6 0, 3 11 0, 33 10, 5 0, 35 10, 1 0, 38 9, 8 0, 4 9, 5 0, 42 9, 3 0, 45 9 0, 47 8, 7
In cats corneal opacities may occur during sedation.
Med sedacijo lahko roženica pri mačkah postane motna.